ID   DU145
AC   CVCL_0105
SY   DU-145; Du-145; DU 145; DU_145; DU.145; Duke University 145
DR   BTO; BTO:0001332
DR   CLO; CLO_0002840
DR   CLO; CLO_0051536
DR   EFO; EFO_0005441
DR   MCCL; MCC:0000140
DR   CLDB; cl1108
DR   CLDB; cl1109
DR   CLDB; cl4961
DR   CLDB; cl5184
DR   AddexBio; C0019004/4984
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-81
DR   BCRC; 60348
DR   BCRJ; 0078
DR   BioGRID_ORCS_Cell_line; 860
DR   BioSample; SAMN03472017
DR   BioSample; SAMN03472041
DR   BioSample; SAMN03472757
DR   BioSample; SAMN05292468
DR   BioSample; SAMN10988253
DR   cancercelllines; CVCL_0105
DR   CCRID; 1101HUM-PUMC000006
DR   CCRID; 3101HUMSCSP5024
DR   CCRID; 3101HUMTCHu222
DR   Cell_Model_Passport; SIDM00120
DR   ChEMBL-Cells; CHEMBL3308034
DR   ChEMBL-Targets; CHEMBL613508
DR   CLS; 300168
DR   Cosmic; 688116
DR   Cosmic; 699306
DR   Cosmic; 704850
DR   Cosmic; 721367
DR   Cosmic; 721558
DR   Cosmic; 755299
DR   Cosmic; 759893
DR   Cosmic; 801349
DR   Cosmic; 809223
DR   Cosmic; 809224
DR   Cosmic; 850415
DR   Cosmic; 850824
DR   Cosmic; 869156
DR   Cosmic; 875891
DR   Cosmic; 876395
DR   Cosmic; 897454
DR   Cosmic; 905935
DR   Cosmic; 911998
DR   Cosmic; 918501
DR   Cosmic; 921050
DR   Cosmic; 922550
DR   Cosmic; 923401
DR   Cosmic; 923956
DR   Cosmic; 943177
DR   Cosmic; 948075
DR   Cosmic; 949247
DR   Cosmic; 974300
DR   Cosmic; 1028649
DR   Cosmic; 1028700
DR   Cosmic; 1057758
DR   Cosmic; 1070887
DR   Cosmic; 1071478
DR   Cosmic; 1071905
DR   Cosmic; 1075274
DR   Cosmic; 1092597
DR   Cosmic; 1172627
DR   Cosmic; 1175887
DR   Cosmic; 1176617
DR   Cosmic; 1212490
DR   Cosmic; 1218869
DR   Cosmic; 1305381
DR   Cosmic; 1312368
DR   Cosmic; 1330912
DR   Cosmic; 1436047
DR   Cosmic; 1481419
DR   Cosmic; 1542078
DR   Cosmic; 1689715
DR   Cosmic; 1712065
DR   Cosmic; 1995389
DR   Cosmic; 1998439
DR   Cosmic; 2580127
DR   Cosmic; 2585152
DR   Cosmic; 2585229
DR   Cosmic; 2592487
DR   Cosmic; 2651768
DR   Cosmic; 2669167
DR   Cosmic; 2674179
DR   Cosmic; 2816220
DR   Cosmic-CLP; 905935
DR   DepMap; ACH-000979
DR   DSMZ; ACC-261
DR   DSMZCellDive; ACC-261
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS077VSE
DR   ENCODE; ENCBS721QHV
DR   GDSC; 905935
DR   GEO; GSM2120
DR   GEO; GSM50224
DR   GEO; GSM50288
DR   GEO; GSM91924
DR   GEO; GSM142455
DR   GEO; GSM142456
DR   GEO; GSM482671
DR   GEO; GSM525794
DR   GEO; GSM648818
DR   GEO; GSM648819
DR   GEO; GSM743479
DR   GEO; GSM750774
DR   GEO; GSM750834
DR   GEO; GSM784791
DR   GEO; GSM799369
DR   GEO; GSM799379
DR   GEO; GSM799432
DR   GEO; GSM799442
DR   GEO; GSM843494
DR   GEO; GSM886988
DR   GEO; GSM888057
DR   GEO; GSM1153440
DR   GEO; GSM1153441
DR   GEO; GSM1181273
DR   GEO; GSM1181302
DR   GEO; GSM1181306
DR   GEO; GSM1181328
DR   GEO; GSM1374469
DR   GEO; GSM1374470
DR   GEO; GSM1669745
DR   GEO; GSM2124639
DR   IARC_TP53; 751
DR   ICLC; HTL99013
DR   IZSLER; BS TCL 141
DR   KCB; KCB 200701YJ
DR   KCLB; 30081
DR   LiGeA; CCLE_356
DR   LINCS_LDP; LCL-1146
DR   Lonza; 761
DR   NCBI_Iran; C428
DR   NCI-DTP; DU-145
DR   PharmacoDB; DU145_309_2019
DR   PRIDE; PXD003105
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0105
DR   PubChem_Cell_line; CVCL_0105
DR   RCB; RCB2143
DR   SKY/M-FISH/CGH; 2792
DR   TKG; TKG 0604
DR   TOKU-E; 1103
DR   Wikidata; Q5206280
RX   CelloPub=CLPUB00698;
RX   PubMed=631930;
RX   PubMed=1574572;
RX   PubMed=1873816;
RX   PubMed=2744886;
RX   PubMed=3335022;
RX   PubMed=3518877;
RX   PubMed=6244232;
RX   PubMed=6935474;
RX   PubMed=7017212;
RX   PubMed=8104329;
RX   PubMed=8510267;
RX   PubMed=9018337;
RX   PubMed=9214606;
RX   PubMed=10700174;
RX   PubMed=10702678;
RX   PubMed=10972993;
RX   PubMed=11135431;
RX   PubMed=11172901;
RX   PubMed=11280753;
RX   PubMed=11304728;
RX   PubMed=11414198;
RX   PubMed=11416159;
RX   PubMed=12606952;
RX   PubMed=12615715;
RX   PubMed=12725112;
RX   PubMed=14518029;
RX   PubMed=15486987;
RX   PubMed=15748285;
RX   PubMed=17088437;
RX   PubMed=17254797;
RX   PubMed=17440963;
RX   PubMed=19372543;
RX   PubMed=20164919;
RX   PubMed=22068913;
RX   PubMed=22275356;
RX   PubMed=22336246;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=23671654;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=23957452;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=26972028;
RX   PubMed=27141528;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=30244336;
RX   PubMed=30629668;
RX   PubMed=30787054;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://en.wikipedia.org/wiki/DU145
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://www.synapse.org/#!Synapse:syn31544441
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=54
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/d/cell-lines-detail-135.html
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 34 hours (Note=At 39th passage) (PubMed=631930); ~29 hours (ATCC=HTB-81); 28-38 hours (CLS=300168); ~30-40 hours (DSMZ=ACC-261); 32.3 hours (NCI-DTP=DU-145); ~29 hours (PBCF); 51.21 hours (GrayJW panel).
CC   HLA typing: A*03:01:01,33:03; B*50:01,57:01:01; C*06:02; DPB1*04:01; DQB1*03:03:02,05:01:01 (PubMed=15748285).
CC   HLA typing: A*33:03,33:03; B*50:01,57:01; C*06:02,06:02; DQB1*05:01,05:01; DRB1*01:01,01:01 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=23671654; PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (PubMed=17088437; ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); ClinVar=VCV001786615; Zygosity=Homozygous (PubMed=17088437; ATCC).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (PubMed=1873816; PubMed=8104329; PubMed=8510267; PubMed=11304728; PubMed=17088437; ATCC).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (PubMed=1873816; PubMed=8104329; PubMed=8510267; PubMed=11304728; PubMed=17088437; ATCC).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: GPI-anchored proteins analysis by proteomics.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.75%; Native American=0%; East Asian, North=2.66%; East Asian, South=0%; South Asian=0.04%; European, North=63.74%; European, South=32.8% (PubMed=30894373).
CC   Misspelling: DU145T; GEO=GSM843494.
CC   Derived from site: Metastatic; Brain; UBERON=UBERON_0000955.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; COG; DSMZ; Genomics_Center_BCF_Technion; KCLB; PubMed=11304728; PubMed=11416159; PubMed=14518029; PubMed=17254797; PubMed=19372543; PubMed=25877200; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D10S1248: 12,13
ST   D12S391: 17,18,20,21
ST   D13S317: 12,13,14 (AddexBio; ATCC; CCRID; CLS; COG; DSMZ; Genomics_Center_BCF_Technion; PubMed=11304728; PubMed=14518029; PubMed=25877200)
ST   D13S317: 12,14 (Cosmic-CLP; KCLB; PubMed=17254797; PubMed=19372543; RCB; TKG)
ST   D16S539: 11,12,13 (Genomics_Center_BCF_Technion)
ST   D16S539: 11,13 (ATCC; CCRID; CLS; COG; DSMZ; PubMed=25877200)
ST   D18S51: 11,12 (PubMed=11304728; PubMed=14518029)
ST   D18S51: 12 (ATCC; CCRID; DSMZ; PubMed=17254797; PubMed=19372543; PubMed=25877200)
ST   D18S51: 12,13 (CLS; Genomics_Center_BCF_Technion)
ST   D19S433: 13 (ATCC; CCRID; DSMZ)
ST   D19S433: 13,14 (Genomics_Center_BCF_Technion)
ST   D1S1656: 14,15,16,17.3
ST   D21S11: 29,30 (PubMed=17254797)
ST   D21S11: 29,30,33 (PubMed=11416159)
ST   D21S11: 30,32,33,34 (Genomics_Center_BCF_Technion; PubMed=14518029)
ST   D21S11: 30,33 (CCRID; DSMZ; PubMed=11304728; PubMed=19372543; PubMed=25877200)
ST   D21S11: 30,33,34 (ATCC; CLS)
ST   D22S1045: 16
ST   D2S1338: 16 (ATCC; CCRID; DSMZ)
ST   D2S1338: 16,17 (Genomics_Center_BCF_Technion)
ST   D2S441: 9,13,14
ST   D3S1358: 16
ST   D5S818: 10,13
ST   D7S820: 7,10,11 (AddexBio; ATCC; CCRID; COG; Cosmic-CLP; DSMZ; Genomics_Center_BCF_Technion; KCLB; PubMed=11304728; PubMed=14518029; PubMed=17254797; PubMed=25877200)
ST   D7S820: 7,10,11,12 (CLS)
ST   D8S1179: 13,14
ST   DYS391: 10
ST   FGA: 21,22,23 (ATCC)
ST   FGA: 21,22 (DSMZ)
ST   FGA: 22 (CCRID; Genomics_Center_BCF_Technion; PubMed=11304728; PubMed=14518029; PubMed=17254797; PubMed=25877200)
ST   FGA: 22,23 (CLS)
ST   Penta D: 9,13
ST   Penta E: 12,14
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 16,17,18 (PubMed=17254797)
ST   vWA: 17,18 (COG; DSMZ; KCLB; PubMed=11304728; PubMed=14518029; PubMed=19372543; PubMed=25877200; TKG)
ST   vWA: 17,18,19 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; Genomics_Center_BCF_Technion; PubMed=11416159; RCB)
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 47
//
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands.
//
RX   PubMed=631930; DOI=10.1002/ijc.2910210305;
RA   Stone K.R., Mickey D.D., Wunderli-Allenspach H., Mickey G.H.,
RA   Paulson D.F.;
RT   "Isolation of a human prostate carcinoma cell line (DU 145).";
RL   Int. J. Cancer 21:274-281(1978).
//
RX   PubMed=1574572; DOI=10.2307/3578273;
RA   Dunphy E.J., Beckett M.A., Thompson L.H., Weichselbaum R.R.;
RT   "Expression of the polymorphic human DNA repair gene XRCC1 does not
RT   correlate with radiosensitivity in the cells of human head and neck
RT   tumor cell lines.";
RL   Radiat. Res. 130:166-170(1992).
//
RX   PubMed=1873816;
RA   Isaacs W.B., Carter B.S., Ewing C.M.;
RT   "Wild-type p53 suppresses growth of human prostate cancer cells
RT   containing mutant p53 alleles.";
RL   Cancer Res. 51:4716-4720(1991).
//
RX   PubMed=2744886; DOI=10.1002/ijc.2910440128;
RA   Hartley-Asp B., Billstrom A., Kruse E.;
RT   "Identification by C-banding of two human prostate tumour cell lines,
RT   1013L and DU 145.";
RL   Int. J. Cancer 44:161-164(1989).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
//
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
//
RX   PubMed=8104329; DOI=10.1002/pros.2990230206;
RA   Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P.;
RT   "p53 oncogene mutations in three human prostate cancer cell lines.";
RL   Prostate 23:123-134(1993).
//
RX   PubMed=8510267; DOI=10.1016/S0022-5347(17)35458-7;
RA   Effert P.J., McCoy R.H., Walther P.J., Liu E.T.;
RT   "p53 gene alterations in human prostate carcinoma.";
RL   J. Urol. 150:257-261(1993).
//
RX   PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::AID-PROS9>3.0.CO;2-H;
RA   Webber M.M., Bello D., Quader S.T.A.;
RT   "Immortalized and tumorigenic adult human prostatic epithelial cell
RT   lines: characteristics and applications Part 2. Tumorigenic cell
RT   lines.";
RL   Prostate 30:58-64(1997).
//
RX   PubMed=9214606; DOI=10.1093/carcin/18.6.1225;
RA   Webber M.M., Bello D., Kleinman H.K., Hoffman M.P.;
RT   "Acinar differentiation by non-malignant immortalized human prostatic
RT   epithelial cells and its loss by malignant cells.";
RL   Carcinogenesis 18:1225-1231(1997).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=10702678; DOI=10.1159/000015432;
RA   Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N.,
RA   Isola J., Visakorpi T., Bergerheim U.S.R., Larsson C.;
RT   "Characterization of chromosomal abnormalities in prostate cancer cell
RT   lines by spectral karyotyping.";
RL   Cytogenet. Cell Genet. 87:225-232(1999).
//
RX   PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H;
RA   Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.;
RT   "Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon
RT   12 deletion variant in malignant human ovarian, prostate, and breast
RT   cancer cell lines.";
RL   Mol. Carcinog. 28:236-246(2000).
//
RX   PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E;
RA   Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D.;
RT   "IPM-FISH, a new M-FISH approach using IRS-PCR painting probes:
RT   application to the analysis of seven human prostate cell lines.";
RL   Genes Chromosomes Cancer 30:143-160(2001).
//
RX   PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3;
RA   Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.;
RT   "The use of multicolor fluorescence technologies in the
RT   characterization of prostate carcinoma cell lines: a comparison of
RT   multiplex fluorescence in situ hybridization and spectral karyotyping
RT   data.";
RL   Cancer Genet. Cytogenet. 124:112-121(2001).
//
RX   PubMed=11280753;
RA   Urasaki Y., Laco G.S., Pourquier P., Takebayashi Y., Kohlhagen G.,
RA   Gioffre C., Zhang H.-L., Chatterjee D., Pantazis P., Pommier Y.;
RT   "Characterization of a novel topoisomerase I mutation from a
RT   camptothecin-resistant human prostate cancer cell line.";
RL   Cancer Res. 61:1964-1969(2001).
//
RX   PubMed=11304728; DOI=10.1002/pros.1045;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.;
RT   "Widely used prostate carcinoma cell lines share common origins.";
RL   Prostate 47:36-51(2001).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.-J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=12606952; DOI=10.1038/sj.onc.1206247;
RA   Clark J., Edwards S., Feber A., Flohr P., John M., Giddings I.,
RA   Crossland S., Stratton M.R., Wooster R., Campbell C., Cooper C.S.;
RT   "Genome-wide screening for complete genetic loss in prostate cancer by
RT   comparative hybridization onto cDNA microarrays.";
RL   Oncogene 22:1247-1252(2003).
//
RX   PubMed=12615715;
RA   Reinhold W.C., Kouros-Mehr H., Kohn K.W., Maunakea A.K., Lababidi S.,
RA   Roschke A.V., Stover K., Alexander J., Pantazis P., Miller L., Liu E.T.,
RA   Kirsch I.R., Urasaki Y., Pommier Y., Weinstein J.N.;
RT   "Apoptotic susceptibility of cancer cells selected for camptothecin
RT   resistance: gene expression profiling, functional analysis, and
RT   molecular interaction mapping.";
RL   Cancer Res. 63:1000-1011(2003).
//
RX   PubMed=12725112; DOI=10.1385/1-59259-372-0:21;
RA   Russell P.J., Kingsley E.A.;
RT   "Human prostate cancer cell lines.";
RL   Methods Mol. Med. 81:21-39(2003).
//
RX   PubMed=14518029; DOI=10.1002/pros.10290;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U.,
RA   Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.;
RT   "Molecular characterization of human prostate carcinoma cell lines.";
RL   Prostate 57:205-225(2003).
//
RX   PubMed=15486987; DOI=10.1002/pros.20158;
RA   Zhao H.-J., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R.,
RA   Brooks J.D.;
RT   "Genome-wide characterization of gene expression variations and DNA
RT   copy number changes in prostate cancer cell lines.";
RL   Prostate 63:187-197(2005).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001;
RA   Azari S., Ahmadi N., Tehrani M.J., Shokri F.;
RT   "Profiling and authentication of human cell lines using short tandem
RT   repeat (STR) loci: report from the National Cell Bank of Iran.";
RL   Biologicals 35:195-202(2007).
//
RX   PubMed=17440963; DOI=10.1002/pros.20581;
RA   Takeda M., Mizokami A., Mamiya K., Li Y.-Q., Zhang J., Keller E.T.,
RA   Namiki M.;
RT   "The establishment of two paclitaxel-resistant prostate cancer cell
RT   lines and the mechanisms of paclitaxel resistance with two cell
RT   lines.";
RL   Prostate 67:955-967(2007).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22275356; DOI=10.1074/jbc.M111.302547;
RA   Lynch T.P., Ferrer C.M., Jackson S.R., Shahriari K.S., Vosseller K.,
RA   Reginato M.J.;
RT   "Critical role of O-linked beta-N-acetylglucosamine transferase in
RT   prostate cancer invasion, angiogenesis, and metastasis.";
RL   J. Biol. Chem. 287:11070-11081(2012).
//
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong D.-X., Yamori T.;
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056;
RA   Lu Y.-H., Soong T.D., Elemento O.;
RT   "A novel approach for characterizing microsatellite instability in
RT   cancer cells.";
RL   PLoS ONE 8:E63056-E63056(2013).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C.,
RA   Wilhelm M., Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=23957452; DOI=10.3109/01913123.2013.814739;
RA   Gilloteaux J., Eze N., Jamison J.M., McGuire K., Summers J.L.;
RT   "A rare, human prostate oncocyte cell originates from the prostatic
RT   carcinoma (DU145) cell line.";
RL   Ultrastruct. Pathol. 37:440-448(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Identification of glycosylphosphatidylinositol-anchored proteins and
RT   omega-sites using TiO2-based affinity purification followed by
RT   hydrogen fluoride treatment.";
RL   J. Proteomics 139:77-83(2016).
//
RX   PubMed=27141528; DOI=10.1016/j.dib.2016.04.001;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Data for identification of GPI-anchored peptides and omega-sites in
RT   cancer cell lines.";
RL   Data Brief 7:1302-1305(2016).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30244336; DOI=10.1007/s00345-018-2501-6;
RA   Samli H., Samli M., Vatansever B., Ardicli S., Aztopal N., Dincel D.,
RA   Sahin A., Balci F.;
RT   "Paclitaxel resistance and the role of miRNAs in prostate cancer cell
RT   lines.";
RL   World J. Urol. 37:1117-1126(2019).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132;
RA   Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P.,
RA   Mitra R., Nonn L., Kimbro K.S., Kittles R.A.;
RT   "Genetic ancestry analysis reveals misclassification of commonly used
RT   cancer cell lines.";
RL   Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//